Nectar Lifesciences Limited (NSE:NECLIFE)

Nectar Lifesciences Financials Overview

Financials in millions INR. Fiscal year is April - March.

Revenue & Profits

Chart

Fiscal Year	TTM	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Mar 31, 2026	Mar 31, 2026	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022
Revenue Revenue Growth	-	-	16,704	16,846	15,237	16,689
Revenue Growth	-	-	-0.84%	10.56%	-8.70%	8.13%
Gross Profit Gross Profit Growth	-	-	2,819	4,650	3,644	4,457
Operating Income Operating Income Growth	-517.54	-517.54	-884.66	928.4	-51.72	1,016
Net Income Net Income Growth	-2,929	-2,929	-1,137	49.95	-241.83	250.47
Earnings Per Share EPS Growth	-13.40	-13.40	-5.07	0.22	-1.08	1.12
EPS Growth	-	-	-	-	-	-

Revenue by Geography

Chart

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022
India India Growth	11,716	11,464	8,453	11,810
Outside India Outside India Growth	7,368	7,795	9,012	7,445
Total Total Growth	19,084	19,258	17,466	19,255

Cash & Debt

Chart

Fiscal Year	Current	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Mar 31, 2026	Mar 31, 2026	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022
Cash & Investments Cash & Investments Growth	1,251	1,251	197.52	203.01	178.94	182.68
Total Debt Total Debt Growth	-	-	5,820	6,355	7,538	8,599
Net Cash (Debt) Net Cash Growth	1,251	1,251	-5,623	-6,152	-7,359	-8,417
Net Cash Growth	-	-	-	-	-	-
Net Cash Per Share Net Cash Per Share Growth	5.72	5.72	-25.07	-27.43	-32.82	-37.53

Cash Flow & CapEx

Chart

Fiscal Year	TTM	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Mar 31, 2026	Mar 31, 2026	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022
Operating Cash Flow Operating Cash Flow Growth	-3,487	-3,487	1,694	2,247	1,337	950.05
Capital Expenditures CapEx Growth	-122.74	-122.74	-437.95	-294.15	-300.6	-249.7
Free Cash Flow Free Cash Flow Growth	-3,610	-3,610	1,256	1,953	1,036	700.35
Free Cash Flow Growth	-	-	-35.66%	88.50%	47.91%	-

Margins

Chart

Fiscal Year	TTM	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Mar 31, 2026	Mar 31, 2026	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022
Gross Margin	-	-	16.88%	27.61%	23.92%	26.71%
Operating Margin	-	-	-5.30%	5.51%	-0.34%	6.09%
Pretax Margin	-	-	-9.67%	1.08%	-2.78%	2.04%
Profit Margin	-	-	-6.81%	0.30%	-1.59%	1.50%
FCF Margin	-	-	7.52%	11.59%	6.80%	4.20%

Valuation

Chart

Fiscal Year	Current	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Aug 2, 2026	Mar 31, 2026	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022
PE Ratio	-	-	-	135.37	-	21.53
P/FCF Ratio	-	-	4.10	3.46	3.45	7.70
PS Ratio	-	-	0.31	0.40	0.24	0.32

Data Source: S&P Global Market Intelligence Last updated: Mar 31, 2026

Financial data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Jul 31, 2026

Data Sources Report a data error